We are live on ! Find out more
PRLD icon

Prelude Therapeutics
PRLD

47 hedge funds and large institutions have $39.1M invested in Prelude Therapeutics in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 23 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more capital invested

Capital invested by funds: $22M → $39.1M (+$17.1M)

0.16% less ownership

Funds ownership: 48.15% → 47.99% (-0.16%)

6% less funds holding

Funds holding: 50 → 47 (-3)

38% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 8

65% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 23

Holders
47
Holders Change
-3
Holders Change %
-6%
% of All Funds
0.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
23
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$901K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$60.4K
3
Prudential Financial
Prudential Financial
New Jersey
+$25.9K
4
SC
Shay Capital
New York
+$25.1K
5
HF
HRT Financial
New York
+$16.9K

Top Sellers

Rank Fund Capital Flow
1
CF
Cantor Fitzgerald
New York
-$171K
2
BlackRock
BlackRock
New York
-$168K
3
UBS Group
UBS Group
Switzerland
-$100K
4
Goldman Sachs
Goldman Sachs
New York
-$70K
5
Charles Schwab
Charles Schwab
California
-$65.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$15.7M – – –
BBA
2
Baker Bros. Advisors
New York
$14.6M – – –
Millennium Management
3
Millennium Management
New York
$1.65M +$901K +898,621 +362%
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.43M +$60.4K +60,284 +6%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$1.26M -$51.4K -51,270 -6%
Renaissance Technologies
6
Renaissance Technologies
New York
$783K -$37.9K -37,800 -6%
Acadian Asset Management
7
Acadian Asset Management
Massachusetts
$777K – – –
Morgan Stanley
8
Morgan Stanley
New York
$409K -$179 -179 -0.1%
BlackRock
9
BlackRock
New York
$382K -$168K -167,586 -39%
Two Sigma Advisers
10
Two Sigma Advisers
New York
$321K -$2.31K -2,300 -1%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$313K – – –
TD Asset Management
12
TD Asset Management
Ontario, Canada
$231K – – –
Two Sigma Investments
13
Two Sigma Investments
New York
$219K -$2.75K -2,744 -2%
SC
14
Shay Capital
New York
$144K +$25.1K +25,000 +33%
State Street
15
State Street
Massachusetts
$141K – – –
Goldman Sachs
16
Goldman Sachs
New York
$114K -$70K -69,851 -47%
GCP
17
GSA Capital Partners
United Kingdom
$108K +$3.79K +3,783 +5%
Manulife (Manufacturers Life Insurance)
18
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$99.7K – – –
BCM
19
Bridgeway Capital Management
Texas
$77K -$35.1K -35,000 -40%
Northern Trust
20
Northern Trust
Illinois
$52.4K -$1.71K -1,706 -4%
Jane Street
21
Jane Street
New York
$50.1K -$57.1K -56,931 -62%
Cerity Partners
22
Cerity Partners
New York
$49.4K -$2.06K -2,060 -6%
Prudential Financial
23
Prudential Financial
New Jersey
$37.2K +$25.9K +25,840 New
HF
24
HRT Financial
New York
$24K +$16.9K +16,901 New
XT
25
XTX Topco
Cayman Islands
$22.4K -$27.1K -26,995 -63%
1
2 3

PRLD Hedge Fund Activity: Q3 2025 in Review

47 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q3 2025, worth a combined $39.1M — up 78% from $22M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of PRLD and 5 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 8 added.

The largest buyer was Millennium Management, adding an estimated $901K. The largest seller was Cantor Fitzgerald, exiting entirely with an estimated $171K sold.

  • 47 institutional investors held Prelude Therapeutics (PRLD) as of Q3 2025, down from 50 in Q2 2025.
  • Funds reported $39.1M of Prelude Therapeutics stock for Q3 2025, up 78% quarter-over-quarter.
  • 5 funds opened new Prelude Therapeutics positions in Q3 2025 and 8 closed out, a net change of -3 holders.
  • The largest Prelude Therapeutics buyer in Q3 2025 was Millennium Management, an estimated $901K added.
  • The largest Prelude Therapeutics seller in Q3 2025 was Cantor Fitzgerald, an estimated $171K sold.

Based on aggregated 13F filings for Q3 2025.